Palisade Bio, Inc.

NasdaqCM PALI

Palisade Bio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024

Palisade Bio, Inc. Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Palisade Bio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -84.27%, a 29.09% change year over year.
Palisade Bio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -118.84%, a -113.40% change year over year.
Palisade Bio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was 887.20%, a 478.00% change year over year.
Palisade Bio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -234.71%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqCM: PALI

Palisade Bio, Inc.

CEO	Mr. J. D. Finley
IPO Date	March 30, 2007
Location	United States
Headquarters	5800 Armada Drive
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Key trends

Past 5 years